Human TIGIT Recombinant Cell Line, HEK293 (CAT#: IOC-LX087)

Creative Biolabs has developed several immune checkpoint stable cell Lines expressing the most popular immune checkpoints to accelerate clients' immunotherapy discovery and clinical translation. Recombinant HEK293 stably expressing human TIGIT (T cell immunoreceptor with Ig and ITIM domains; VSTM3; VSIG9), GenBank Accession #NM_173799. Which can be used in binding assays and functional assay.

Stable cell lines for increased reliability and reproducibility;
Protein expression at the cell surface validated by FACS or WB;

Screening for TIGIT binding molecules (such as anti-TIGIT antibody) in a cellular context.

Human

HEK293

TIGIT

TIGIT is a co-inhibitory receptor that is highly expressed in Natural Killer (NK) cells, activated CD4+, CD8+ and regulatory T cells. Interaction with the poliovirus receptor (PVR; CD155) on antigen presenting cells, such as dendritic cells, recruits Src homology (SH) domain-containing protein tyrosine phosphatase SHP1 and SHP2 or the inositol phosphatase SHIP1 and SHIP2 to the TIGIT ITIM domain. This increases IL-10 release and suppresses NF-kB and NFAT T cell receptor (TCR) signaling, which blocks T cell proliferation and cytokine production. It serves as a competitive inhibitor of CD226, a co-stimulatory receptor for CD155. TIGIT targeting antibodies that block this T cell-intrinsic inhibitory effects have shown enhanced anti-tumor and anti-viral functions in preclinical studies.